Condition: Relapsed/Refractory Diffuse Large B-Cell Lymphoma · Sponsor: Hutchmed
This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.
This description comes directly from the study's public registry record.
Dongmei Chen, CPL · 86-21-20671794 · dongmeic@hutch-med.com
Always discuss trial participation with your own doctor first.
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
| Baoding NO.1 Central Hospital | Baoding, China | Recruiting |
| Beijing GoBroad Hospital | Beijing, China | Recruiting |
| BEIJING TONGREN HOSPITAL, Capital Medical University | Beijing, China | Recruiting |
| The First Affiliated Hospital of Bengbu Medical College | Bengbu, China | Recruiting |
| The First Hospital of Jilin University | Changchun, China | Recruiting |
| Hunan Cancer Hospital | Changsha, China | Recruiting |
| People's Hospital of Hunan Province | Changsha, China | Recruiting |
| The Second Xiangya Hospital of Central South University | Changsha, China | Recruiting |
| Sichuan Provincial People's Hospital | Chengdu, China | Recruiting |
| West China Hospital of Sichuan University | Chengdu, China | Recruiting |
| Chongqing University Cancer Hospital | Chongqing, China | Recruiting |
+ 38 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07409428